Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Biological Explanation of Clinically Observed Elevation of TFPI Plasma Levels After Treatment with TFPI-Antagonistic Aptamer BAX 499

Michael Dockal, PhD, Robert Pachlinger, Rudolf Hartmann, PhD, Sabine Knappe, PhD, Benny Sorensen, Wing Yen Wong, Maureen Conlan, Michael Cecerle, Bruce M. Ewenstein, MD PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2012) 120 (21): 1104.

https://doi.org/10.1182/blood.V120.21.1104.1104

Published: 2012

Journal Articles

Importance of Measuring Circulating ADAMTS13 Immune Complexes in Addition to Free Antibodies in Patients with Acquired TTP

Silvia Ferrari, PhD, Barbara Plaimauer, PhD, Bernadette Gruber, Kristina Palavra, Peter L Turecek, PhD, Hartmut J. Ehrlich, MD, Hanspeter Rottensteiner, PhD, Friedrich Scheiflinger, PhD

Blood (2012) 120 (21): 102.

https://doi.org/10.1182/blood.V120.21.102.102

Published: 2012

Journal Articles

Structure-Activity Relationship of Pro- and Anticoagulant Effects of Fucus Vesiculosus Fucoidan

Michael Dockal, PhD, Susanne Till, PhD, Zhenqing Zhang, Sabine Knappe, PhD, Sabrina Reutterer, Catherine Quinn, Christoph Redl, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Christina Szabo

Blood (2012) 120 (21): 3353.

https://doi.org/10.1182/blood.V120.21.3353.3353

Published: 2012

Journal Articles

Effect of Increased Tissue Factor Pathway Inhibitor (TFPI) Levels On Factor Xa Inhibition and Global Hemostasis in the Presence of TFPI-Antagonistic Aptamer BAX 499.

Michael Dockal, PhD, Rudolf Hartmann, PhD, Sabine Knappe, PhD, Michael Palige, PhD, Willibald Kammlander, PhD, Klara Kunckova, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2012) 120 (21): 2207.

https://doi.org/10.1182/blood.V120.21.2207.2207

Published: 2012

Journal Articles

Glycosylphosphatidylinositol Anchored TFPI As Main Regulator of Factor X Activation On the Surface of Endothelial Cells.

Michael Dockal, PhD, Robert Pachlinger, Angelina Baldin-Stoyanova, Fabian Knofl, Nadja Ullrich, Jadranka Koehn, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2012) 120 (21): 2210.

https://doi.org/10.1182/blood.V120.21.2210.2210

Published: 2012

Journal Articles

Structural and Functional Characterization of Fucoidan and Its Procoagulant Effect in An Ex Vivo Model of Factor VIII-Inhibited Guinea Pigs

Michael Dockal, PhD, Werner Hoellriegl, Zhenqing Zhang, Susanne Till, PhD, Sabine Knappe, PhD, Michael Palige, PhD, Alexandra Schiviz, Hartmut J. Ehrlich, MD, Christina Szabo, Eva-Maria Muchitsch, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 2262.

https://doi.org/10.1182/blood.V118.21.2262.2262

Published: 2011

Journal Articles

Peptides Inhibiting Tissue Factor Pathway Inhibitor Improve Hemostasis in Mice

Michael Dockal, PhD, Rudolf Hartmann, PhD, Thomas Polakowski, MBA, Osterkamp Frank, Hartmut J. Ehrlich, MD, Alexandra Schiviz, Werner Hoellriegl, Eva-Maria Muchitsch, Ulrich Reinecke, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 24.

https://doi.org/10.1182/blood.V118.21.24.24

Published: 2011

Journal Articles

Peptides Binding to Kunitz Domain 1 of Tissue Factor Pathway Inhibitor (TFPI) Inhibit All Functions of TFPI and Improve Thrombin Generation of Hemophilia Plasma

Michael Dockal, PhD, Johannes Brandstetter, PhD, Martin Ludwiczek, Georg Kontaxis, PhD, Markus Fries, PhD, M C L G D Thomassen, PhD, A Heinzmann, PhD, Hartmut J. Ehrlich, MD, Katerina Prohaska, Rudolf Hartmann, PhD, Jan Rosing, Professor, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 2245.

https://doi.org/10.1182/blood.V118.21.2245.2245

Published: 2011

Journal Articles

Strong Correlation of High Endogenous Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) with Poor Blood Clotting and Corrective Action of BAX 513 Under FVIII-Inhibited Conditions

Michael Dockal, PhD, Monika Gorczyca, PhD, Sabine Knappe, PhD, Michael Palige, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Bernd Jilma, MD

Blood (2011) 118 (21): 1201.

https://doi.org/10.1182/blood.V118.21.1201.1201

Published: 2011

Journal Articles

Anticoagulant Activity and Mechanism of Non-Anticoagulant Sulfated Polysaccharides

Michael Dockal, PhD, Susanne Till, PhD, Sabine Knappe, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 1208.

https://doi.org/10.1182/blood.V118.21.1208.1208

Published: 2011

Journal Articles

Safety of Baxter’s Longer Acting rFVIII (BAX 855) After Repeated Application in Rats and Cynomolgus Monkeys

Barbara Dietrich, DVM, Margit Spatzenegger, PhD, Reinhard Stidl, PhD, Martin Wolfsegger, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4345.

https://doi.org/10.1182/blood.V118.21.4345.4345

Published: 2011

Journal Articles

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

Gerald Hoebarth, DVM, Susan Kubik, BSc, Martin Wolfsegger, PhD, John-Philip Lawo, Alfred Weber, PhD, Herbert Gritsch, Werner Hoellriegl, Alexandra Schiviz, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4346.

https://doi.org/10.1182/blood.V118.21.4346.4346

Published: 2011

Journal Articles

Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A

Alexandra Schiviz, Eder Barbara, John-Philip Lawo, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, Werner Hoellriegl

Blood (2011) 118 (21): 4350.

https://doi.org/10.1182/blood.V118.21.4350.4350

Published: 2011

Journal Articles

Structural Characterization of BAX 855, a PEGylated Recombinant FVIII

Martin Kaliwoda, PhD, Michael Graninger, PhD, Peter Matthiessen, PhD, Gerald Schrenk, PhD, Peter L Turecek, PhD, Artur Mitterer, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 4356.

https://doi.org/10.1182/blood.V118.21.4356.4356

Published: 2011

Journal Articles

Preclinical Safety Pharmacology of Baxter’s Longer Acting rFVIII (BAX 855)

Barbara Dietrich, DVM, Susan Kubik, BSc, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4357.

https://doi.org/10.1182/blood.V118.21.4357.4357

Published: 2011

Journal Articles

Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats

Reinhard Stidl, PhD, Juergen Siekmann, PhD, Sean M Culbertson, Tony Vinson, Antoni Kozlowski, Xiaoming Shen, Mary J Bossard, Hanspeter Rottensteiner, PhD, Barbara Dietrich, DVM, Chyung Cook, Peter L Turecek, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4358.

https://doi.org/10.1182/blood.V118.21.4358.4358

Published: 2011

Journal Articles

Functional Characterization of BAX 855, a PEGylated Recombinant FVIII

Gerald Schrenk, PhD, Katalin Varadi, PhD, Herbert Gritsch, Hanspeter Rottensteiner, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 4359.

https://doi.org/10.1182/blood.V118.21.4359.4359

Published: 2011

Journal Articles

2D-DIGE As a Tool to Analyze Lot-to-Lot Consistency of Complex Therapeutic Products Such As BAX 855, a PEGylated Recombinant FVIII

Hanspeter Rottensteiner, PhD, Christina Monetti, Herbert Gritsch, Alfred Weber, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 4360.

https://doi.org/10.1182/blood.V118.21.4360.4360

Published: 2011

Journal Articles

Detection of Circulating ADAMTS13 Immune Complexes by Antibody Class-Specific ELISA

Barbara Plaimauer, PhD, Silvia Ferrari, Bernadette Gruber, Hanspeter Rottensteiner, PhD, Peter L Turecek, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 4361.

https://doi.org/10.1182/blood.V118.21.4361.4361

Published: 2011

Journal Articles

Development of a Large Scale Production Process for BAX 855, a PEGylated rFVIII Product with Prolonged Half-Life

Jürgen Siekmann, PhD, Purtscher Martin, PhD, Oliver Zöchling, Robert Kellerer, Hanspeter Rottensteiner, PhD, Artur Mitterer, PhD, Marry Bossard, PhD, Gayle Phillips, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 4362.

https://doi.org/10.1182/blood.V118.21.4362.4362

Published: 2011

NARROW

Biological Explanation of Clinically Observed Elevation of TFPI Plasma Levels After Treatment with TFPI-Antagonistic Aptamer BAX 499

Importance of Measuring Circulating ADAMTS13 Immune Complexes in Addition to Free Antibodies in Patients with Acquired TTP

Structure-Activity Relationship of Pro- and Anticoagulant Effects of Fucus Vesiculosus Fucoidan

Effect of Increased Tissue Factor Pathway Inhibitor (TFPI) Levels On Factor Xa Inhibition and Global Hemostasis in the Presence of TFPI-Antagonistic Aptamer BAX 499.

Glycosylphosphatidylinositol Anchored TFPI As Main Regulator of Factor X Activation On the Surface of Endothelial Cells.

Structural and Functional Characterization of Fucoidan and Its Procoagulant Effect in An Ex Vivo Model of Factor VIII-Inhibited Guinea Pigs

Peptides Inhibiting Tissue Factor Pathway Inhibitor Improve Hemostasis in Mice

Peptides Binding to Kunitz Domain 1 of Tissue Factor Pathway Inhibitor (TFPI) Inhibit All Functions of TFPI and Improve Thrombin Generation of Hemophilia Plasma

Strong Correlation of High Endogenous Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) with Poor Blood Clotting and Corrective Action of BAX 513 Under FVIII-Inhibited Conditions

Anticoagulant Activity and Mechanism of Non-Anticoagulant Sulfated Polysaccharides

Safety of Baxter’s Longer Acting rFVIII (BAX 855) After Repeated Application in Rats and Cynomolgus Monkeys

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A

Structural Characterization of BAX 855, a PEGylated Recombinant FVIII

Preclinical Safety Pharmacology of Baxter’s Longer Acting rFVIII (BAX 855)

Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats

Functional Characterization of BAX 855, a PEGylated Recombinant FVIII

2D-DIGE As a Tool to Analyze Lot-to-Lot Consistency of Complex Therapeutic Products Such As BAX 855, a PEGylated Recombinant FVIII

Detection of Circulating ADAMTS13 Immune Complexes by Antibody Class-Specific ELISA

Development of a Large Scale Production Process for BAX 855, a PEGylated rFVIII Product with Prolonged Half-Life

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only